Evolus, Inc. (0K16.L)

USD 11.39

(0.03%)

Total Debt Summary of Evolus, Inc.

  • Evolus, Inc.'s latest annual total debt in 2023 was 126.54 Million USD , up 72.88% from previous year.
  • Evolus, Inc.'s latest quarterly total debt in 2024 Q2 was 126.75 Million USD , up 0.08% from previous quarter.
  • Evolus, Inc. reported annual total debt of 73.19 Million USD in 2022, down -2.07% from previous year.
  • Evolus, Inc. reported annual total debt of 74.74 Million USD in 2021, down -45.96% from previous year.
  • Evolus, Inc. reported quarterly total debt of 126.75 Million USD for 2024 Q2, up 0.08% from previous quarter.
  • Evolus, Inc. reported quarterly total debt of 95.09 Million USD for 2023 Q3, down -1.79% from previous quarter.

Annual Total Debt Chart of Evolus, Inc. (2023 - 2015)

Historical Annual Total Debt of Evolus, Inc. (2023 - 2015)

Year Total Debt Total Debt Growth
2023 126.54 Million USD 72.88%
2022 73.19 Million USD -2.07%
2021 74.74 Million USD -45.96%
2020 138.31 Million USD 43.27%
2019 96.54 Million USD 471.14%
2018 16.9 Million USD -92.0%
2017 211.32 Million USD 253.62%
2016 59.76 Million USD 29.44%
2015 46.16 Million USD 0.0%

Peer Total Debt Comparison of Evolus, Inc.

Name Total Debt Total Debt Difference
Editas Medicine, Inc. 36.53 Million USD -246.36%
Dynavax Technologies Corporation 256.91 Million USD 50.744%
Supernus Pharmaceuticals, Inc. 41.52 Million USD -204.732%
Perrigo Company plc 4.07 Billion USD 96.893%
Illumina, Inc. 2.26 Billion USD 94.406%
Thermo Fisher Scientific Inc. 34.91 Billion USD 99.638%
Iovance Biotherapeutics, Inc. 1 Million USD -12554.6%
Walgreens Boots Alliance, Inc. 9.55 Billion USD 98.675%
IQVIA Holdings Inc. 14.23 Billion USD 99.111%
Heron Therapeutics, Inc. 173.75 Million USD 27.169%
Regeneron Pharmaceuticals, Inc. 2.7 Billion USD 95.318%
Unity Biotechnology, Inc. 26.99 Million USD -368.863%
Waters Corporation 2.35 Billion USD 94.628%
Biogen Inc. 7.33 Billion USD 98.276%
Sangamo Therapeutics, Inc. 38.1 Million USD -232.107%
Adicet Bio, Inc. 17.7 Million USD -614.828%
Cara Therapeutics, Inc. 43.16 Million USD -193.154%
bluebird bio, Inc. 330.32 Million USD 61.691%
Esperion Therapeutics, Inc. 540.94 Million USD 76.607%
FibroGen, Inc. 170.45 Million USD 25.76%
Agilent Technologies, Inc. 2.73 Billion USD 95.373%
Corbus Pharmaceuticals Holdings, Inc. 20.88 Million USD -505.94%
Homology Medicines, Inc. 44.05 Million USD -187.252%
Geron Corporation 85.89 Million USD -47.32%
Alnylam Pharmaceuticals, Inc. 2.39 Billion USD 94.723%
Amicus Therapeutics, Inc. 445.05 Million USD 71.566%
Myriad Genetics, Inc. 145 Million USD 12.727%
Viking Therapeutics, Inc. 1.26 Million USD -9943.333%
Intellia Therapeutics, Inc. 115.34 Million USD -9.71%
Zoetis Inc. 6.8 Billion USD 98.14%
Abeona Therapeutics Inc. 4.4 Million USD -2774.739%
Mettler-Toledo International Inc. 2.16 Billion USD 94.162%
BioMarin Pharmaceutical Inc. 1.13 Billion USD 88.84%
Vertex Pharmaceuticals Incorporated 808.4 Million USD 84.346%
Kala Pharmaceuticals, Inc. 36.32 Million USD -248.391%
Ionis Pharmaceuticals, Inc. 1.45 Billion USD 91.294%
Atara Biotherapeutics, Inc. 57.87 Million USD -118.665%
Verastem, Inc. 41.55 Million USD -204.512%
Nektar Therapeutics 230.4 Million USD 45.076%
Axsome Therapeutics, Inc. 186.37 Million USD 32.1%
Aclaris Therapeutics, Inc. 3.07 Million USD -4016.656%
Sarepta Therapeutics, Inc. 1.39 Billion USD 90.94%
OPKO Health, Inc. 326.56 Million USD 61.249%
Exelixis, Inc. 189.94 Million USD 33.377%
Neurocrine Biosciences, Inc. 428.4 Million USD 70.461%
Corcept Therapeutics Incorporated 151 Thousand USD -83705.298%
Anavex Life Sciences Corp. - USD -Infinity%
uniQure N.V. 138.4 Million USD 8.571%
Imunon, Inc. 1.13 Million USD -11007.415%
Blueprint Medicines Corporation 774.12 Million USD 83.653%
Insmed Incorporated 1.2 Billion USD 89.489%
Halozyme Therapeutics, Inc. 1.49 Billion USD 91.559%
Agios Pharmaceuticals, Inc. 56.98 Million USD -122.057%
TG Therapeutics, Inc. 110.79 Million USD -14.216%
Incyte Corporation 38.28 Million USD -230.519%
Emergent BioSolutions Inc. 877.5 Million USD 85.579%